Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin containing immunotoxins.
Newton
D L
DL
SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Room 162, Building 567, Frederick, MD 21702-1201, USA.
Hansen
H J
HJ
Liu
H
H
Ruby
D
D
Iordanov
M S
MS
Magun
B E
BE
Goldenberg
D M
DM
Rybak
S M
SM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology; D015815:Cell Adhesion Molecules; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry / Q000627:therapeutic use*; D037102:Lectins; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D012313:RNA / Q000378:metabolism; D012260:Ribonucleases / Q000627:therapeutic use*; D051918:Sialic Acid Binding Ig-like Lectin 2
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D000922:Immunotoxins; D037102:Lectins; D051918:Sialic Acid Binding Ig-like Lectin 2; D012313:RNA; D012260:Ribonucleases